Skip to main content

zorevunersen

Generic: STK-001·Code: STK-001

zorevunersen: sourced relationships with 1 company · 2 clinical trials tracked.

zorevunersen evidence translation

What we can confirm

2 tracked trials

What it means

Source-backed records connect zorevunersen to BIIB; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could zorevunersen → BIIB affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Dravet syndrome
Dated Pipeline Records (1)
CompanyDated record stage
BIOGEN INC. (BIIB)
co_developer · Reported 2026-02-06 · Current development: unknownSource
Dravet syndrome
Phase 3
Clinical Trial Registry Records (2)

EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome

NCT06872125Registry updated 2026-08-24·Phase 3·STOK
Recruiting

Primary endpoint: Measurement of Seizure Change

InterventionalRandomizedquadruple170 targetStarted 2025-06Completion 2028-1050 sites · China, France, Germany, Italy…Stoke Therapeutics, Inc

An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001

NCT04740476Registry updated 2026-02-04·Phase 2·STOK

Primary endpoint: Safety of multiple doses of zorevunersen

Interventionalopen60 targetStarted 2021-01Completion 2029-0317 sites · United StatesStoke Therapeutics, Inc

Frequently asked questions

Which companies have sourced relationships with zorevunersen?

zorevunersen has dated SEC/FDA relationship records for BIOGEN INC..

How many clinical trials involve zorevunersen?

BioSniper tracks 2 clinical trials involving zorevunersen.